Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BTN3A1/CD277 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BTN3A1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native glycosylation. |
View BTN3A1 Products |
| Gene Delivery | BTN3A1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and conformational flow cytometry assays. |
View BTN3A1 Products |
| Benchmark Ab | Anti-BTN3A1 Recombinant Antibody Sequence derived from clinical benchmark ICT01. Ideal positive control for activation assays. |
View BTN3A1 Products |
| Validator | BTN3A1 siRNA Set Target-specific knockdown pool for specificity and functional validation. |
View BTN3A1 Products |
| Related Target A | BTN2A1 Essential co-factor that binds phosphoantigens and associates with BTN3A1 to initiate Vγ9Vδ2 T-cell activation. |
View BTN2A1 Products |
| Related Target B | BTN3A2 / BTN3A3 High-homology subfamily members. Critical for off-target counter-screening and selectivity assays. |
View BTN3A2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Cross-Reactivity (BTN3A1 vs BTN3A2/3) | Homolog panel proteins (BTN3A2, BTN3A3) strictly verified by mass spectrometry and sequence purity. |
| Conformational Dependent Binding | HEK293-expressed ECD-Fc proteins preserve native post-translational modifications. Lentivirus platforms enable full-length membrane presentation. |
| Lack of Controls | Clinical Benchmark Antibodies (ICT01 biosimilar) included to validate assay sensitivity. |
| False Positives | Sequence-verified siRNA pools ensure high-efficiency target gene silencing with minimal off-target effects. |
Live BTN3A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BTN3A1/CD277 therapeutics is intensifying, with major players shifting focus from traditional checkpoint inhibitors to Gamma-Delta (γδ) T-cell engagers and allogeneic cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the intracellular B30.2 domain dynamics and the cooperative binding mechanism with BTN2A1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb | ImCheck Therapeutics (ICT01) | Solid Tumors, Hematologic Malignancies | Activation Assay (Need high-purity ECD-Fc & BTN2A1 co-proteins) |
| Bispecific / γδ-TCE | LAVA Therapeutics | Prostate Cancer, Multiple Myeloma | Heterodimer Validation (Need cross-reactive antigens & stable cell lines) |
| Allogeneic Cell Therapy | Adicet Bio | B-cell Lymphoma | Target Expression Verification (Need validated siRNA & Lentivirus) |